NVO
Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 110.81$. Average daily volumn in 3 months 1.51M. Market cap 244.30B
Stock symbol : NVO. Exchange : NYSE. Currency : USD Lastest price : 107.75$. Total volume : 2.29M. Market state POSTPOST Click reload if you want to check the lastest price on market!!!
Novo Nordisk A/S (NVO)
Last Price
107.75$Change
3.70Volume
2.29M
| Previous Close | 104.05 |
| Open | 106.53 |
| Day Range | 106.35-108.22 |
| Bid | 105.10 x 1k |
| Ask | 108.12 x 1.8k |
| Volume | 2.29M |
| Average Volume | 1.51M |
| Market Cap | 244.3B |
| Beta | 0.25 |
| 52 Week Range | 78.71-122.16 |
| Trailing P/E | 35.26 |
| Foward P/E | 27.49 |
| Dividend (Yield %) | 1.46% |
| Ex-Dividend Date | 2022-03-25 |
Financial Details
Organization
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Market Cap:
244.30BRevenue:
140.8BTotal Assets:
194.51BTotal Cash:
10.72B
News about "Novo Nordisk A/S"
Equities Analysts Set Expectations for Novo Nordisk A/S’s FY2024 Earnings (NYSE:NVO)
Source from : Defense World - 2 days ago
Jefferies Financial Group increased their FY2024 earnings per share estimates for Novo Nordisk A/S in a research report issued on Monday, May 16th. Jefferies Financial Group analyst P. Welford now ...See details»
Here’s Our Rant About Novo Nordisk A/S (NVO)
Source from : newsheater - 7 days ago
Novo Nordisk A/S (NYSE:NVO) went up by 0.52% from its latest closing price compared to the recent 1-year high of $122.16. The company’s stock price has collected -7.48% of loss in the last five ...See details»
Jefferies Financial Group Weighs in on Novo Nordisk A/S’s Q2 2022 Earnings (NYSE:NVO)
Source from : Defense World - 3 days ago
Equities research analysts at Jefferies Financial Group cut their Q2 2022 EPS estimates for shares of Novo Nordisk A/S in a research note issued to investors on Monday, May 16th. Jefferies Financial ...See details»
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Source from : YAHOO!Finance - 9 days ago
This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation ...See details»
Novo Nordisk A/S’s (NYSE:NVO) Stock Gains 0.77%: A Look At Its Most Probable Path Moving Forward
Source from : stocksregister - 8 days ago
Novo Nordisk A/S (NYSE:NVO) shares, rose in value on Thursday, May 12, with the stock price up by 0.77% to the previous day’s close as strong demand from buyers drove the stock to $104.61. Actively ...See details»
Cowen Upgrades Novo Nordisk A/S (NYSE:NVO) to Outperform
Source from : ETF Daily News - 25 days ago
Novo Nordisk A/S (NYSE:NVO – Get Rating) last announced its quarterly earnings results on Wednesday, February 2nd.The company reported $0.73 earnings per share (EPS) for the quarter, beating the ...See details»
Novo Nordisk A/S: Share repurchase programme
Source from : Yahoo Finance - 4 days ago
On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»
Human Recombinant Insulin Market Progresses for Huge Profits by 2028 | Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A.
Source from : Digital Journal - 2 days ago
Global Human Recombinant Insulin Market 2022 research report study entails a thorough examination of the industry’s future and current conditions. The ...See details»
Novo Nordisk A/S:
Source from : Yahoo News - 14 days ago
Bagsværd, Denmark, 6 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 29 April 2022 holds B shares equal to 5.06% of the ...See details»
How Novo Nordisk Will Protect Insulin Sales
Source from : Nasdaq - 8 days ago
President Biden discussed capping insulin prices at $35 a month, and the House followed suit by passing the Affordable Insulin Now Act at the end of March. Opponents point out that much of the ...See details»
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
Source from : Nasdaq - 17 hours ago
The stock has risen 6.8% this year so far. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Novo Nordisk: Novo Nordisk has one of the broadest diabetes portfolios in ...See details»
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Source from : YAHOO!Finance - 7 days ago
Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and three of the largest pharmacy benefit managers (PBMs) of artificially driving up insulin prices. The complaint, filed by Arkansas Attorney ...See details»
Smart insulin is the future: Vikrant Shrotriya of Novo Nordisk
Source from : Moneycontrol on MSN.com - 1 days ago
If taking an insulin injection every day is difficult for a diabetes patient, a once-a-week option would probably be more acceptable in the future.See details»
Assessing the impact of economic shocks on the Novo Nordisk A/S share price
Source from : Yahoo News UK - 5 days ago
A question on the minds of many investors right now is how economic uncertainty will continue to affect large cap companies, such as Novo Nordisk A/S ...See details»